Laura M. Kulik, MD, Northwestern

Articles

Final Thoughts on the Future of Liver Cancer

April 8th 2021

A panel of experts lead by Richard S. Finn, MD, provide their final thoughts on the future of advanced unresectable liver cancer.

Challenges of Sequencing and Biomarkers in Hepatocellular Carcinoma

April 8th 2021

Experts provide insight into the challenges of sequencing and biomarkers when treating advanced HCC.

Role of Single Agent IO in Hepatocellular Carcinoma Frontline Therapies

April 8th 2021

A summary of ongoing clinical data that explore the use of frontline single agent immunotherapy in advanced HCC.

HCC Treatment: Emerging Data in IO Combinations

April 1st 2021

Experts discuss emerging data in immunotherapy combination approaches for the treatment of advanced HCC.

Ongoing Data for First-line Combinations in HCC

April 1st 2021

A summary of updates that explore ongoing data from various frontline combinations in unresectable HCC.

Role of TKIs in HCC Treatment

March 25th 2021

An examination of the use of second-line therapies after atezolizumab-bevacizumab, and the role of TKIs for the treatment of advanced HCC.

Treatment Strategies for Childs-Pugh B Disease

March 25th 2021

Experts expand on treatment strategies and sequencing approaches used for Child-Pugh B liver disease.

Considerations for Later Lines of Therapy in HCC Treatment

March 18th 2021

Experts in the field of HCC consider second and third lines of therapy after a patient’s disease state progresses after frontline atezolizumab-bevacizumab.

Personal Experience Using Atezolizumab-Bevacizumab in HCC Treatment

March 18th 2021

Laura M. Kulik, MD, leads a discussion about personal experiences using atezolizumab-bevacizumab and whether clinical trial data reflect real-world experience.

A New Standard of Care for Liver Cancer Treatment

March 11th 2021

A discussion about the recent data from trials that looked at atezolizumab-bevacizumab for the treatment of advanced HCC, and its role as the new standard of care.